Regenxbio Q3 revenue falls on lower ZOLGENSMA royalties
Overview
US gene therapy developer's Q3 revenue declined yr/yr, mainly due to lower ZOLGENSMA royalties
Q3 net loss narrowed compared to prior year quarter
Company recorded $38 mln gain from Sarepta litigation settlement
Outlook
Company expects current cash resources to fund operations into late Q4 2027
Company expects topline data from pivotal wet AMD trials in Q4 2026
Result Drivers
ROYALTY DECLINE - Co said revenue drop was mainly due to lower ZOLGENSMA royalties following U.S. patent expiration
HIGHER R&D SPENDING - Co said increased R&D costs were mainly due to RGX-202 clinical trial expenses
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 License & Royalty Revenue | $5.24 mln | ||
Q3 Net Loss | $40.74 mln | ||
Q3 Operating Expenses | $44.70 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for REGENXBIO Inc. is $20.00, about 159.4% above its November 4 closing price of $7.71
Reuters Recommended Reads
Nov 2 - FDA to review uniQure's Huntington's gene therapy, decision due on May 2027
Nov 4 - Netherlands' uniQure Q3 revenue misses estimates
Nov 3 - Denali Therapeutics swings to Q3 net profit on one-time gain
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)